James H Boyum1, Thomas D Atwell2, Grant D Schmit1, John J Poterucha3, Cathy D Schleck4, W Scott Harmsen4, Patrick S Kamath3. 1. Department of Radiology, Mayo Clinic, Rochester, MN. 2. Department of Radiology, Mayo Clinic, Rochester, MN. Electronic address: Atwell.Thomas@mayo.edu. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To determine the incidence of major adverse events related to a large volume of image-guided liver biopsies performed at our institution over a 12-year period and to identify risk factors for major bleeding events. PATIENTS AND METHODS: A retrospective analysis of an internally maintained biopsy registry was performed. The analysis revealed that 6613 image-guided liver biopsies were performed in 5987 adult patients between December 7, 2001, and December 31, 2013. Liver biopsies were performed using real-time ultrasound guidance and a spring-loaded biopsy device, with rare exceptions. Adverse events considered major and included in this study were hematoma, infection, pneumothorax, hemothorax, and death. Using data from the biopsy registry, we evaluated statistically significant risk factors (P<.05) for hematoma related to image-guided liver biopsy, including coagulation status, biopsy technique, and medications. RESULTS: A total of 49 acute and delayed major adverse events (0.7%) occurred after 6613 liver biopsy events. The incidence of hematoma requiring transfusion and/or angiographic intervention was 0.5% (34 of 6613). The incidence of infection was 0.1% (8 of 6613), and that of hemothorax was 0.06% (4 of 6613). No patient (0%) incurred a pneumothorax after biopsy. Three patients (0.05%) died within 30 days of liver biopsy, 1 being directly related to biopsy. Thirty-eight of 46 major adverse events (83%) presented acutely (within 24 hours). More than 2 biopsy passes, platelets 50,000/μL or less, and female sex were statistically significant risk factors for postbiopsy hemorrhage. CONCLUSION: Image-guided liver biopsy performed by subspecialized interventionalists at a tertiary medical center is safe when the platelet count is greater than 50,000/μL. With appreciation of specific risk factors, safety outcomes of this procedure can be optimized in both general and specialized centers.
OBJECTIVE: To determine the incidence of major adverse events related to a large volume of image-guided liver biopsies performed at our institution over a 12-year period and to identify risk factors for major bleeding events. PATIENTS AND METHODS: A retrospective analysis of an internally maintained biopsy registry was performed. The analysis revealed that 6613 image-guided liver biopsies were performed in 5987 adult patients between December 7, 2001, and December 31, 2013. Liver biopsies were performed using real-time ultrasound guidance and a spring-loaded biopsy device, with rare exceptions. Adverse events considered major and included in this study were hematoma, infection, pneumothorax, hemothorax, and death. Using data from the biopsy registry, we evaluated statistically significant risk factors (P<.05) for hematoma related to image-guided liver biopsy, including coagulation status, biopsy technique, and medications. RESULTS: A total of 49 acute and delayed major adverse events (0.7%) occurred after 6613 liver biopsy events. The incidence of hematoma requiring transfusion and/or angiographic intervention was 0.5% (34 of 6613). The incidence of infection was 0.1% (8 of 6613), and that of hemothorax was 0.06% (4 of 6613). No patient (0%) incurred a pneumothorax after biopsy. Three patients (0.05%) died within 30 days of liver biopsy, 1 being directly related to biopsy. Thirty-eight of 46 major adverse events (83%) presented acutely (within 24 hours). More than 2 biopsy passes, platelets 50,000/μL or less, and female sex were statistically significant risk factors for postbiopsy hemorrhage. CONCLUSION: Image-guided liver biopsy performed by subspecialized interventionalists at a tertiary medical center is safe when the platelet count is greater than 50,000/μL. With appreciation of specific risk factors, safety outcomes of this procedure can be optimized in both general and specialized centers.
Authors: Mohammed Hadi; Carolina Walker; Michael Desborough; Antonio Basile; Dimitrios Tsetis; Beverley Hunt; Stefan Müller-Hüllsbeck; Thomas Rand; Otto van Delden; Raman Uberoi Journal: Cardiovasc Intervent Radiol Date: 2021-01-20 Impact factor: 2.740
Authors: Ricardo Holderbaum do Amaral; Fabrice C Deprez; João Pedro Dalla-Bona; Guilherme Watte; Rômulo Santos Roxo; Edson Marchiori; Bruno Hochhegger Journal: Radiol Bras Date: 2021 May-Jun
Authors: Gil Ben Yakov; Disha Sharma; Hawwa Alao; Pallavi Surana; Devika Kapuria; Ohad Etzion; Matthew M Hsieh; John F Tisdale; Courtney D Fitzhugh; David E Kleiner; Elliot B Levy; Richard Chang; Elenita Rivera; Amy Huang; Christopher Koh; Theo Heller Journal: Br J Haematol Date: 2019-06-19 Impact factor: 8.615
Authors: James Neuberger; Jai Patel; Helen Caldwell; Susan Davies; Vanessa Hebditch; Coral Hollywood; Stefan Hubscher; Salil Karkhanis; Will Lester; Nicholas Roslund; Rebecca West; Judith I Wyatt; Mathis Heydtmann Journal: Gut Date: 2020-05-28 Impact factor: 23.059